JANUVIA's oppositions filed in EPO
JANUVIA Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6699871 | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 9 months ago) | |
| US7326708 | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6303661 | MERCK SHARP DOHME | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(7 years ago) | |
| US7459428 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US6890898 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7078381 | MERCK SHARP DOHME | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7125873 | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 9 months ago) | |
|
US7125873 (Pediatric) | MERCK SHARP DOHME | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 3 months ago) | |
|
US6699871 (Pediatric) | MERCK SHARP DOHME | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 3 months ago) | |
|
US7326708 (Pediatric) | MERCK SHARP DOHME | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
Januvia is owned by Merck Sharp Dohme.
Januvia contains Sitagliptin Phosphate.
Januvia has a total of 10 drug patents out of which 8 drug patents have expired.
Expired drug patents of Januvia are:
- US6303661
- US7459428
- US6890898
- US7078381
- US7125873
- US7125873*PED
- US6699871*PED
- US6699871
Januvia was authorised for market use on 16 October, 2006.
Januvia is available in tablet;oral dosage forms.
Januvia can be used as method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin and/or a sulfonylurea, improvement of glycemic control in adults with type 2 diabetes mellitus, improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin and/or a ppar-gamma agonist and/or sulfonylurea and/or insulin, improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin., method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor.
Drug patent challenges can be filed against Januvia from 05 June, 2023.
The generics of Januvia are possible to be released after 24 May, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
| M(M-244) | Aug 12, 2022 |
Drugs and Companies using
SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date:
Market Authorisation Date:
16 October, 2006Treatment:
Improvement of glycemic control in adults with type 2 diabetes mellitus; Improvement of glycemic control in adults with type 2 diabetes mellitus in combination with metformin.; Improvement of glycemic...Dosage:
How can I launch a generic of JANUVIA before its drug patent expiration?
More Information on Dosage
JANUVIA family patents
